These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36802845)

  • 1. Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE-IT.
    Olshansky B; Bhatt DL; Miller M; Steg PG; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Kowey PR; Reiffel JA; Tardif JC; Ballantyne CM; Chung MK;
    J Am Heart Assoc; 2023 Mar; 12(5):e026756. PubMed ID: 36802845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL.
    Majithia A; Bhatt DL; Friedman AN; Miller M; Steg PG; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Budoff M; Preston Mason R; Tardif JC; Boden WE; Ballantyne CM
    Circulation; 2021 Nov; 144(22):1750-1759. PubMed ID: 34706555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI.
    Peterson BE; Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Gibson CM; Pinto D; Giugliano RP; Budoff MJ; Tardif JC; Verma S; Ballantyne CM;
    J Am Heart Assoc; 2022 Mar; 11(6):e022937. PubMed ID: 35261279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG.
    Verma S; Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Dhingra NK; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Gibson CM; Pinto D; Giugliano RP; Budoff MJ; Mason RP; Tardif JC; Ballantyne CM;
    Circulation; 2021 Dec; 144(23):1845-1855. PubMed ID: 34710343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction.
    Gaba P; Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Tardif JC; Giugliano RP; Martens FMAC; Gibson CM; Ballantyne CM;
    J Am Coll Cardiol; 2022 May; 79(17):1660-1671. PubMed ID: 35483753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
    Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Ballantyne CM;
    N Engl J Med; 2019 Jan; 380(1):11-22. PubMed ID: 30415628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking.
    Miller M; Bhatt DL; Steg PG; Brinton EA; Jacobson TA; Jiao L; Tardif JC; Ballantyne CM; Budoff M; Mason RP
    Eur Heart J Cardiovasc Pharmacother; 2023 Feb; 9(2):129-137. PubMed ID: 35953437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT.
    Gaba P; Bhatt DL; Giugliano RP; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Tardif JC; Ballantyne CM; Pinto DS; Budoff MJ; Gibson CM
    J Am Coll Cardiol; 2021 Oct; 78(15):1525-1537. PubMed ID: 34620410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States.
    Bhatt DL; Miller M; Brinton EA; Jacobson TA; Steg PG; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Olshansky B; Chung MK; Gibson CM; Giugliano RP; Budoff MJ; Ballantyne CM;
    Circulation; 2020 Feb; 141(5):367-375. PubMed ID: 31707829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
    Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Gregson J; Pocock SJ; Ballantyne CM;
    J Am Coll Cardiol; 2019 Jun; 73(22):2791-2802. PubMed ID: 30898607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE-IT.
    Selvaraj S; Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Juliano RA; Jiao L; Tardif JC; Ballantyne CM;
    J Am Heart Assoc; 2022 Apr; 11(7):e024999. PubMed ID: 35377160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
    Chapman MJ; Zamorano JL; Parhofer KG
    Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn.
    Miller M; Bhatt DL; Brinton EA; Jacobson TA; Steg PG; Pineda AL; Ketchum SB; Doyle RT; Tardif JC; Ballantyne CM
    Eur Heart J Open; 2023 Nov; 3(6):oead114. PubMed ID: 38035037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses.
    Peterson BE; Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Gibson CM; Pinto D; Giugliano RP; Budoff MJ; Tardif JC; Verma S; Ballantyne CM;
    Circulation; 2021 Jan; 143(1):33-44. PubMed ID: 33148016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
    Trivedi K; Le V; Nelson JR
    Postgrad Med; 2021 Jan; 133(1):28-41. PubMed ID: 32762268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT.
    Gaba P; Bhatt DL; Mason RP; Miller M; Verma S; Steg PG; Boden WE;
    J Clin Lipidol; 2022; 16(4):389-402. PubMed ID: 35773147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid (RESPECT-EPA).
    Miyauchi K; Iwata H; Nishizaki Y; Inoue T; Hirayama A; Kimura K; Ozaki Y; Murohara T; Ueshima K; Kuwabara Y; Tanaka-Mizuno S; Yanagisawa N; Sato T; Daida H;
    Circulation; 2024 Aug; 150(6):425-434. PubMed ID: 38873793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial.
    Vilain K; Li H; Kwong WJ; Antman EM; Ruff CT; Braunwald E; Cohen DJ; Giugliano RP; Magnuson EA;
    Circ Cardiovasc Qual Outcomes; 2020 Nov; 13(11):e006511. PubMed ID: 33148013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial.
    Bahit MC; Vora AN; Li Z; Wojdyla DM; Thomas L; Goodman SG; Aronson R; Jordan JD; Kolls BJ; Dombrowski KE; Vinereanu D; Halvorsen S; Berwanger O; Windecker S; Mehran R; Granger CB; Alexander JH; Lopes RD
    JAMA Cardiol; 2022 Jul; 7(7):682-689. PubMed ID: 35612866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial.
    Zelniker TA; Bonaca MP; Furtado RHM; Mosenzon O; Kuder JF; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Budaj A; Kiss RG; Padilla F; Gause-Nilsson I; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
    Circulation; 2020 Apr; 141(15):1227-1234. PubMed ID: 31983236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.